NCT06928818 Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
| NCT ID | NCT06928818 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Cancer of Breast |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-02-26 |
| Primary Completion | 2028-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-02-26 with a primary completion date of 2028-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea
Eligibility Criteria
Inclusion Criteria: * HER2-positive, advanced (unresectable locally advanced or metastatic) breast cancer * Prior treatment with trastuzumab deruxtecan(T-DXd) in the advanced setting * Intention to treat with Trastuzumab Emtansine (T-DM1) as first therapy upon T-DXd progression Exclusion Criteria: * Any systemic treatment, other than T-DM1, for breast cancer after trastuzumab deruxtecan (As an exception, patients treated with endocrine agents, not in combination with cytotoxics or antibody-drug conjugates, will be permitted in the study) * Has been previously treated with T-DM1 for advanced breast cancer * Has been previously treated with 4 or more lines of therapy for advanced breast cancer * Half (50%) or more patients will be those who were treated with second-line trastuzumab deruxtecan (i.e. patients at the later line will be capped).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06928818 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Cancer of Breast. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06928818 currently recruiting?
Yes, NCT06928818 is actively recruiting participants. Contact the research team at kyunghunlee@snu.ac.kr for enrollment information.
Where is the NCT06928818 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06928818 clinical trial?
NCT06928818 is sponsored by Seoul National University Hospital. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.